Campbell Alliance Report on 2015 Trends in Biopharmaceutical Dealmaking Reveals Areas of Greatest Opportunity for Buyers and Sellers
Much-Anticipated Annual Dealmakers’ Intentions Study From inVentiv Health Consulting Firm to be Released at 2015 BIO International Convention
NEW YORK – June 11, 2015 – Campbell Alliance, the consulting firm of inVentiv Health, will release the results from its seventh annual Dealmakers’ Intentions Study and review the greatest opportunities for buyers and sellers of biopharmaceutical assets during a panel at this year’s BIO International Convention in Philadelphia. A presentation of the study results will take place during a Super Session on Thursday, June 18, 2015, at 10:00 a.m. in room 114.
The Dealmakers’ Intentions 2015 Study includes input from all major segments of the biopharmaceutical industry. It captures expectations for deal activity throughout the rest of 2015, explores supply and demand for assets at different stages of development and reviews various approaches to valuation. For example, the study notes that buyers’ demand for preclinical and phase III assets overshadows supply across several therapeutic areas which will likely result in significant increase in asset value this year. The study also found sellers possessed a more optimistic outlook than buyers for the balance of 2015.
“The level of dealmaking activity in 2014 was the highest it has been since 2009 and this year’s activity is set to surpass it,” said Neel Patel, Vice President, Campbell Alliance. “But this time, M&A activity is being fueled by small and mid-cap biopharma buyers, who are flush with cash. And the details of what we found across the sector should be of interest to anyone looking to buy or sell an asset in 2015.”
Entitled “Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?,” the session will also involve a panel discussion with industry experts, including David Donabedian, Vice President, Head of Ventures and Early Stage Collaborations, AbbVie; Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence; Patrick Verheyen, Global Head, Business Development, Janssen Pharmaceutical Companies of Johnson & Johnson; and Timothy P. Walbert, Chairman, President and Chief Executive Officer, Horizon Pharma.
While the record pace of licensing/acquisitions has continued into 2015, there have been early signals of a potential slowdown. These signals include increased expectations of acquisitions with earn-outs over outright acquisitions and greater financing options available to emerging companies, which pose a viable alternative to licensing.
For additional information about Dealmakers' Intentions 2015, including access to a white paper summary of the results, visit inVentiv Health booth #837 at the BIO conference or inVentivHealth.com/CampbellAlliance/BIO2015 and follow #Dealmakers2015 on Twitter.
About Campbell Alliance
Campbell Alliance is the Consulting arm of inVentiv Health and an industry leader in biopharmaceutical consulting. The firm's clients include all of the world's top 20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into five Practice Areas – Commercial Excellence, Commercial Strategy, Market Access, Medical and Corporate Development – each of which offers a range of services to a critical area of the pharmaceutical and biotechnology industries. Each of our Practice Areas has a dedicated consulting team whose members are highly specialized and offer deep expertise in their chosen areas. From its 13 office locations, the firm serves clients throughout North America, Europe and Asia. For more information on Campbell Alliance, please visit inVentivHealth.com/CampbellAlliance.
About inVentiv Health
inVentiv Health is a top-tier professional services organization that accelerates the clinical and commercial success of biopharmaceutical companies worldwide. Our combined Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) helps clients improve their performance to deliver much-needed therapies to market. With 13,000 employees providing services to clients in 70 countries, inVentiv Health designs best practices, processes and systems to enable clients to successfully navigate an increasingly complex environment. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv Health management team.
For more information, visit www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and terminations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our debt instruments and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.